Pediatric and Adult Translational Cancer Drug Discovery and Development Training Program (PACT-D3)

儿童和成人转化癌症药物发现和开发培训计划 (PACT-D3)

• 批准号: 10708526
• 负责人: David W Clapp
• 金额: $ 15.88万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708526
• 关键词: Adult; Antineoplastic Agents; Childhood; Training Programs; drug development; drug discovery

Abstract This training program is unique for our institution, creating the next generation of basic and clinical investigators who focus their efforts on strategic and comprehensive drug discovery and development in cancer. This program capitalizes on a strong infrastructure and institutional commitment to the training of graduate student trainees for careers in pediatric and adult drug discovery and development. The addition of a pediatric cancer focus addresses an unmet need as well as a major focus of NCI as determined by the NCI's board of scientific advisors and the resulting Childhood Cancer Data (CCDI) initiative. The wealth of adult experience and pediatric researchers is uniquely being used in this T32 to develop novel approaches in pediatric drug discovery. There are no current NCI T32s with an emphasis on both pediatric and adult cancer drug discovery and development training. Cancer remains the leading cause of disease-related death in children. For the many children who experience relapses of their malignant solid tumors curative treatment options are scarce. The pediatric efforts will dovetail with the multi-institutional “Developmental and HyperActive Ras Tumor (DHART)” SPORE led by multi-PI Dr. Wade Clapp focusing on neurofibromatosis type 1 (NF1)—the most common human genetic cancer predisposition syndrome. Findings in this SPORE have led to new clinical trials for pediatric patients, and it is anticipated additional new drugs will need to be developed that is beyond the scope of the SPORE. In addition, the NIH/NICHD-funded P50, “Specialized Centers in Research in Pediatric Developmental Pharmacology” is using precision genomics strategies and in vivo modeling to design efficacious and safe combination therapies for relapsed solid tumors such as osteosarcoma and additional new targets for potential drug development are being identified. This highlights our focus and opportunity to identify new drug targets and develop new drugs specifically for pediatric patients. This program will be supported by collaborative efforts from other programs at the IU School of Medicine (IUSM) including the NCI designated IU Simon Comprehensive Cancer Center (IUSCCC); the Cancer Drug Discovery and Development (CDDD) center which is embedded in the IUSCCC Experimental and Developmental Therapeutics (EDT) program; the TaRget Engagement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) Center and the Indiana CTSI Preclinical Innovation “Think Tank” program. We will focus on graduate students as trainees, who will be recruited from two centralized programs that oversee graduate student recruitment and guide trainees in selecting mentors and home departments. These two programs are the Indiana BioMedical Gateway (IBMG) program, which enrolls ~36 graduate students per year and MSTP which enrolls ~10 per year. Eighteen mentors are intimately involved in this program and drug development efforts at the school. The goal of PACT-D3 is focused on grooming the next generation of diverse, basic, and translational researchers with interests in pediatric and adult cancer drug discovery and development.

抽象的 该培训计划对于我们机构是独一无二的，创建了下一代基本和临床研究人员 他们将精力集中在癌症的战略和综合药物发现和发展上。这个程序 利用强大的基础设施和机构承诺，以培训研究生学员的培训 小儿和成人药物发现与发育的职业。增加儿科癌症的焦点 解决了NCI科学委员会确定的未满足需求以及NCI的主要重点 顾问和由此产生的儿童癌症数据（CCDI）倡议。成人经验和小儿的财富 在此T32中，研究人员正在独特地使用小儿药物发现中的新方法。那里 目前没有NCI T32，重点是儿科和成人癌症药物发现和发育 训练。癌症仍然是儿童与疾病有关的主要原因。对于许多孩子 其恶性实体瘤治疗选择的经验接力很少。小儿努力 将与多机构的“发育和多动性Ras肿瘤（DHART）”孢子索引。 多人韦德·克拉普（Wade Clapp）博士专注于1型神经纤维瘤病（NF1） - 最常见的人类遗传癌 倾向综合征。该孢子的发现导致了儿科患者的新临床试验，这是 需要开发出预期的其他新药，这超出了孢子的范围。此外， NIH/NICHD资助的P50，“小儿发展药理学研究专业中心”是 使用精确的基因组学策略和体内建模来设计高效且安全的组合疗法 对于接力实体瘤，例如骨肉瘤和潜在药物开发的其他新靶标的是 被确定。这凸显了我们识别新药物和开发新药的重点和机会 专为儿科患者。该计划将得到其他计划的协作努力的支持 IU医学院（IUSM），包括NCI指定的IU Simon综合癌症中心 （IUSCCC）;嵌入在IUSCCC中的癌症药物发现与发育（CDDD）中心 实验和发育治疗（EDT）计划；加速治疗的目标参与 阿尔茨海默氏病（Treat-AD）中心和印第安纳州CTSI临床前创新的发展 坦克“计划。我们将专注于研究生作为培训，他们将从两个集中式的 监督研究生招聘和指导学员选择导师和家庭的计划 部门。这两个计划是印第安纳生物医学门户（IBMG）计划，该计划招收〜36 每年研究生和MSTP每年约10个。十八位导师密切参与 这项计划和药物开发工作在学校。 PACT-D3的目的是重新修饰下一个 产生潜水员，基本和翻译的研究人员，对小儿和成人癌症药物有兴趣 发现与发展。